Provenge
(Sipuleucel-T)Phase 3Cell therapy
Sipuleucel-T is used to treat advanced prostate cancer in men whose cancer no longer responds to hormone therapy. It works by boosting the patient's own immune system to fight the cancer cells.[1] Provenge is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Provenge is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.
1
Indications
33
Total Trials
6
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Xaluritamig
AmgenPhase 3
Provenge
PProstate Oncology Specialists, Inc.
Phase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer21 trials
Show 18 more trials
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Recruiting·—·Phase 1·NCT07219147·30 enrolled
Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
Completed·—·Phase 1·NCT02036918·20 enrolled
Metastatic Prostate Cancer6 trials
mCRPC1 trial
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02463799·36 enrolled
Concentration1 trial
3 more indications
Metastatic Castration-Resistant Prostate Cancer1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sipuleucel-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details